Pharmacogenomics of CYP3A: considerations for HIV treatment

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  van Heeswijk RP: Optimized antiretroviral therapy: the role of therapeutic drug monitoring and pharmacogenomics. Expert Rev. Anti Infect. Ther.1,75–81 (2003).
  Medline CASGoogle Scholar
• 2  Acosta EP, Gerber JG: Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res. Hum. Retroviruses18,825–834 (2002).
  Medline CASGoogle Scholar
• 3  Catanzaro L, Slish J, Dicenzo R, Morse G: Drug interactions with antiretrovirals. Curr. HIV/AIDS Rep.1,89–96 (2004).▪ Along with [4] provides the comprehensive insight into the drug interaction in antiretroviral therapy.
  MedlineGoogle Scholar
• 4  Boffito M, Acosta E, Burger D et al.: Therapeutic drug monitoring and drug–drug interactions involving antiretroviral drugs. Antivir Ther.10,469–477 (2005).▪ Along with [3] provides the comprehensive insight into the drug interaction in antiretroviral therapy.
  Medline CASGoogle Scholar
• 5  Wertheimer BZ, Freedberg KA, Walensky RP, Yazdanapah Y, Losina E: Therapeutic drug monitoring in HIV treatment: a literature review. HIV Clin. Trials7,59–69 (2006).
  MedlineGoogle Scholar
• 6  Droste JA, Koopmans PP, Hekster YA, Burger DM: TDM: therapeutic drug measuring or therapeutic drug monitoring? Ther. Drug Monit.27,412–416 (2005).
  Medline CASGoogle Scholar
• 7  Burger D, Hugen P, Reiss P et al.: Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS17,1157–1165 (2003).
  Medline CASGoogle Scholar
• 8  Morse G, Catanzaro L, Acosta E: Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy. Lancet Infect. Dis.6,215–225 (2006).▪ Therapeutic drug monitoring may provide a mechanism for individualizing the clinical pharmacodynamics of protease inhibitors based on patient-specific viral susceptibility.
  Medline CASGoogle Scholar
• 9  Bruce RD, Altice FL: Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir. AIDS20,783–784 (2006).
  MedlineGoogle Scholar
• 10  Bruce RD, Altice FL, Gourevitch MN, Friedland GH: Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J. Acquir. Immune Defic. Syndr.41,563–572 (2006).
  Medline CASGoogle Scholar
• 11  Surratt HL, Inciardi JA, Weaver JC, Falu VM: Emerging linkages between substance abuse and HIV infection in St. Croix, US Virgin Islands. AIDS Care17(Suppl. 1),S26–S35 (2005).
  MedlineGoogle Scholar
• 12  Beyrer C: Epidemiology Update and Transmission Factors. XVI International AIDS Conference. (2006).
  Google Scholar
• 13  Chawarski MC, Mazlan M, Schottenfeld RS: Heroin dependence and HIV infection in Malaysia. Drug Alcohol. Depend.82(Suppl. 1),S39–S42 (2006).
  MedlineGoogle Scholar
• 14  Saylors K, Jim N, Plasencia AV, Smith D: Faces of HIV/AIDS and substance abuse in Native American communities. J. Psychoactive Drugs37,241–246 (2005).
  MedlineGoogle Scholar
• 15  Kapadia F, Vlahov D, Donahoe RM, Friedland G: The role of substance abuse in HIV disease progression: reconciling differences from laboratory and epidemiologic investigations. Clin. Infect. Dis.41,1027–1034 (2005).
  MedlineGoogle Scholar
• 16  Sullivan LE, Metzger DS, Fudala PJ, Fiellin DA: Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users. Addiction100,150–158 (2005).
  MedlineGoogle Scholar
• 17  Francis H: Substance abuse and HIV infection. Top. HIV Med.11,20–24 (2003).
  MedlineGoogle Scholar
• 18  Kerr T, Wodak A, Elliott R, Montaner JS, Wood E: Opioid substitution and HIV/AIDS treatment and prevention. Lancet364,1918–1919 (2004).
  MedlineGoogle Scholar
• 19  Verachai V, Phutiprawan T, Sawanpanyalert P: HIV infection among substance abusers in Thanyarak Institute On Drug Abuse, Thailand, 1987–2002. J. Med. Assoc. Thai.88,76–79 (2005).
  MedlineGoogle Scholar
• 20  Mccance-Katz EF: Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents. Clin. Infect. Dis.41(Suppl. 1),S89–S95 (2005).
  Medline CASGoogle Scholar
• 21  Bruce R, Mccance-Katz E, Kharasch E, Moody D, Morse G: Pharmacokinetic interactions between buprenorphine and antiretroviral medications. Clin. Infect. Dis.43,S216–S223 (2006).
  Medline CASGoogle Scholar
• 22  Baker J, Best A, Pade P, Mccance-Katz E: Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients. Ann. Pharmacother.40,392–396 (2006).
  Medline CASGoogle Scholar
• 23  Flexner CW: Advances in HIV pharmacology: protein binding, pharmacogenomics, and therapeutic drug monitoring. Top. HIV Med.11,40–44 (2003).
  MedlineGoogle Scholar
• 24  Burger DM, van Rossum AM, Hugen PW et al.: Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children. Antimicrob. Agents Chemother.45,701–705 (2001).
  Medline CASGoogle Scholar
• 25  Cholerton S, Daly A, Idle J: The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol. Sci.13,434–439 (1992).
  Medline CASGoogle Scholar
• 26  Xie H-G, Wood AJ, Kim RB, Stein CM, Wilkinson GR: Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics5,243–272 (2004).
  CASGoogle Scholar
• 27  Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC: The human intestinal cytochrome P450 ‘pie’. Drug Metab. Dispos.34,880–886 (2006).
  Medline CASGoogle Scholar
• 28  Lamba JK, Lin YS, Schuetz EG, Thummel KE: Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev.54,1271–1294 (2002).▪▪ Possible importance of CYP3A5 variants in the regulation, drug metabolism, efficacy and safety.
  Medline CASGoogle Scholar
• 29  Spurr N, Gough A, Stevenson K, Wolf CR: The human cytochrome P450 CYP3 locus: assignment to chromosome 7q22-qter. Hum Genet.81,171–174 (1989).
  Medline CASGoogle Scholar
• 30  Haehner BD, Gorski JC, Vandenbranden M et al.: Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol. Pharmacol.50,52–59 (1996).
  Medline CASGoogle Scholar
• 31  Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther.270,414–423 (1994).
  Medline CASGoogle Scholar
• 32  Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab. Rev.34,83–448 (2002).
  Medline CASGoogle Scholar
• 33  Thummel KE, Kunze KL, Shen DD: Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv. Drug Deliv. Rev.27,99–127 (1997).
  Medline CASGoogle Scholar
• 34  Guengerich F: Cytochrome P-450 3A4: regulation and role in drug metabolism. Ann. Rev. Pharmacol. Toxicol.39,1–17 (1999).▪▪ Elucidation of the determinants of CYP3A activity, because of the interindividual variability present in the activity and its involvement in the metabolism of a large number of drugs.
  Medline CASGoogle Scholar
• 35  Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl Cancer Inst.90,1225–1229 (1998).
  Medline CASGoogle Scholar
• 36  Kuehl P, Zhang J, Lin Y et al.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet.27,383–391 (2001).
  Medline CASGoogle Scholar
• 37  Gonzalez FJ, Schmid BJ, Umeno M et al.: Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. DNA7,79–86 (1988).
  Medline CASGoogle Scholar
• 38  Walker A, Jaffe J, Gunasegaram S, Cummings SA, Huang CS, Chern H: Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online. Hum. Mutat.12,289 (1998).
  Medline CASGoogle Scholar
• 39  Hsieh K-P, Lin Y-Y, Cheng C-L et al.: Novel mutations of CYP3A4 in Chinese. Drug Metab. Dispos.29,268–273 (2001).
  Medline CASGoogle Scholar
• 40  Ball SE, Scatina J, Kao J et al.: Population distribution and effects on drug metabolism of a genetic variant in the 5´ promoter region of CYP3A4. Clin. Pharmacol. Ther.66,288–294 (1999).
  Medline CASGoogle Scholar
• 41  García-Martín E, Maartnez C, Pizarro RM et al.: CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin. Pharmacol. Ther.71,196–204 (2002).
  Medline CASGoogle Scholar
• 42  Paris PL, Kupelian PA, Hall JM et al.: Association between a CYP3A4 genetic variant and clinical presentation in African–American prostate cancer patients. Cancer Epidemiol. Biomarkers Prev.8,901–905 (1999).
  Medline CASGoogle Scholar
• 43  Sata F, Sapone A, Elizondo G et al.: CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin. Pharmacol. Ther.67,48–56 (2000).
  Medline CASGoogle Scholar
• 44  Hamzeiy H, Vahdati-Mashhadian N, Edwards HJ, Goldfarb PS: Mutation analysis of the human CYP3A4 gene 5´ regulatory region: population screening using non-radioactive SSCP. Mutat. Res.500,103–110 (2002).
  Medline CASGoogle Scholar
• 45  Saeki M, Saito Y, Nakamura T et al.: Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in a Japanese population. Hum. Mutat.21,653–670 (2003).
  MedlineGoogle Scholar
• 46  Fukushima-Uesaka H, Saito Y, Watanabe H et al.: Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum. Mutat.23,100–108 (2004).
  MedlineGoogle Scholar
• 47  Nelson DR, Koymans L, Kamataki T et al.: P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics6,1–42 (1996).
  Medline CASGoogle Scholar
• 48  Inoue K, Inazawa J, Nakagawa Het al.: Assignment of the human cytochrome P-450 nifedipine oxidase gene (CYP3A4) to chromosome 7 at band q22.1 by fluorescence in situ hybridization. Jpn. J. Hum. Genet.37,133–138 (1992).
  Medline CASGoogle Scholar
• 49  Shchepotina EG, Vavilin VA, Goreva OB, Lyakhovich VV: Some mutations of exon-7 in cytochrome P450 gene 3A4 and their effect on 6β-hydroxylation of cortisol. Bull. Exp. Biol. Med.141,701–703 (2006).
  Medline CASGoogle Scholar
• 50  Reyes-Hernández OD, Lares-Asseff I, Sosa-Macias M, Vega L, Albores A, Elizondo G: A comparative study of CYP3A4 polymorphisms in Mexican Amerindian and Mestizo populations. Pharmacol. Ther.81,97–103 (2008).
  CASGoogle Scholar
• 51  van Schaik R, van der Heiden I, van den Anker J, Lindemans J: CYP3A5 variant allele frequencies in Dutch Caucasians. Clin. Chem.48,1668–1671 (2002).
  Medline CASGoogle Scholar
• 52  Eiselt R, Domanski Tl, Zibat A et al.: Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics11,447–458 (2001).
  Medline CASGoogle Scholar
• 53  Murayama N, Nakamura T, Saeki M et al.: CYP3A4 gene polymorphisms influence testosterone 6β-hydroxylation. Drug Metab. Pharmacokinet.17,150–156 (2002).
  Medline CASGoogle Scholar
• 54  Dai D, Tang J, Rose R et al.: Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J. Pharmacol. Exp. Ther.299,825–831 (2001).
  Medline CASGoogle Scholar
• 55  Lee S-J, Bell DA, Coulter SJ, Ghanayem B, Goldstein JA: Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype. J. Pharmacol. Exp. Ther.313,302–309 (2005).
  Medline CASGoogle Scholar
• 56  Westlind-Johnsson A, Hermann R, Huennemeyer A et al.: Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity. Clin. Pharmacol. Ther.79,339–349 (2006).
  Medline CASGoogle Scholar
• 57  Jounaidi Y, Guzelian PS, Maurel P, Vilarem MJ: Sequence of the 5´-flanking region of CYP3A5: comparative analysis with CYP3A4 and CYP3A7. Biochem. Biophy. Res. Commun.205,1741–1747 (1994).
  Medline CASGoogle Scholar
• 58  Paulussen A, Lavrijsen K, Bohets H et al.: Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. Pharmacogenetics10,415–424 (2000).
  Medline CASGoogle Scholar
• 59  Lee S-J, Usmani K, Chanas B et al.: Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics13,461–472 (2003).
  Medline CASGoogle Scholar
• 60  Jounaïdi Y, Hyrailles V, Gervot L, Maurel P: Detection of a CYP3A5 allelic variant: a candidate for the polymorphic expression of the protein? Biochem. Biophy. Res. Commun.221,466–470 (1996).
  Medline CASGoogle Scholar
• 61  Hustert E, Haberl M, Burk O et al.: The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics11,773–779 (2001).
  Medline CASGoogle Scholar
• 62  van Schaik Rh, de Wildt SN, Brosens R, van Fessem M, van den Anker JN, Lindemans J: The CYP3A4*3 allele: is it really rare? Clin. Chem.47,1104–1106 (2001).
  Medline CASGoogle Scholar
• 63  Hesselink DA, van Schaik RH, van der Heiden IP et al.: Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther.74,245–254 (2003).
  Medline CASGoogle Scholar
• 64  Thervet E, Anglicheau D, King B et al.: Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation76,1233–1235 (2003).
  Medline CASGoogle Scholar
• 65  Kivistö KT, Niemi M, Schaeffeler E et al.: Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics14,523–525 (2004).
  MedlineGoogle Scholar
• 66  Balram C, Zhou Q, Cheung Y, Lee E: CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations. Eur. J. Clin. Pharmacol.59,123–126 (2003).
  Medline CASGoogle Scholar
• 67  Hiratsuka M, Takekuma Y, Endo N et al.: Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur. J. Clin. Pharmacol.58,417–421 (2002).
  Medline CASGoogle Scholar
• 68  Roy J-N, Lajoie J, Zijenah LS et al.: CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab. Dispos.33,884–887 (2005).
  Medline CASGoogle Scholar
• 69  Chou F-C, Tzeng S-J, Huang J-D: Genetic polymorphism of cytochrome P450 3A5 in Chinese. Drug Metab. Dispos.29,1205–1209 (2001).
  Medline CASGoogle Scholar
• 70  Shih P-S, Huang J-D: Pharmacokinetics of midazolam and 1´-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab. Dispos.30,1491–1496 (2002).
  Medline CASGoogle Scholar
• 71  Wong M, Balleine Rl, Collins M, Liddle C, Clarke Cl, Gurney H: CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clin. Pharmacol. Ther.75,529–538 (2004).
  Medline CASGoogle Scholar
• 72  Mirghani R, Sayi J, Aklillu E et al.: CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population. Pharmacogenet. Genomics16,637–645 (2006).
  Medline CASGoogle Scholar
• 73  Lee S-J, van der Heiden IP, Goldstein JA, van Schaik RHN: a new CYP3A5 variant, CYP3A5*11, is shown to be defective in nifedipine metabolism in a recombinant cDNA expression system. Drug Metab. Dispos.35,67–71 (2007).
  Medline CASGoogle Scholar
• 74  Domanski T, Finta C, Halpert JR, Zaphiropoulos PG: cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol. Pharmacol.59,386–392 (2001).
  Medline CASGoogle Scholar
• 75  Daly A, Cholerton S, Gregory W, Idle J: Metabolic polymorphisms. Pharmacol. Ther.57,129–160 (1993).
  Medline CASGoogle Scholar
• 76  Cauffiez C, Lo-Guidice J, Chevalier D et al.: First report of a genetic polymorphism of the cytochrome P450 3A43 (CYP3A43) gene: identification of a loss-of-function variant. Hum. Mutat.23,101–108 (2004).
  MedlineGoogle Scholar
• 77  Zeigler-Johnson C, Friebel T, Walker AH et al.: CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Res.64,8461–8467 (2004).
  Medline CASGoogle Scholar
• 78  Kliewer SA, Moore JT, Wade L et al.: An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell92,73–82 (1998).
  Medline CASGoogle Scholar
• 79  Blumberg B, Sabbagh Jr W, Juguilon H et al.: SXR, a novel steroid and xenobiotic sensing nuclear receptor. Genes Dev.12,3195–3205 (1998).
  Medline CASGoogle Scholar
• 80  Bertilsson G, Berkenstam A, Blomquist P: Functionally conserved xenobiotic responsive enhancer in cytochrome P450 3A7. Biochem. Biophys. Res. Commun.280,139–144 (2001).
  Medline CASGoogle Scholar
• 81  Lehmann J, Mckee D, Watson M, Willson T, Moore J, Kliewer S: The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest.102,1016–1023 (1998).
  Medline CASGoogle Scholar
• 82  Burk O, Wojnowski L: Cytochrome P450 3A and their regulation. Naunyn Schmiedebergs Arch. Pharmacol.369,105–124 (2004).
  Medline CASGoogle Scholar
• 83  Burk O, Koch I, Raucy J et al.: The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J. Biol. Chem.279,38379–38385 (2004).
  Medline CASGoogle Scholar
• 84  Burk O, Tegude H, Koch I et al.: Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J. Biol. Chem.277,24280–24288 (2002).
  Medline CASGoogle Scholar
• 85  El-Sankary W, Gibson GG, Ayrton A, Plant N: Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers. Drug Metab. Dispos.29,1499–1504 (2001).
  Medline CASGoogle Scholar
• 86  Luo G, Cunningham M, Kim S et al.: CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab. Dispos.30,795–804 (2002).
  Medline CASGoogle Scholar
• 87  Hebert M, Roberts J, Prueksaritanont T, Benet L: Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin. Pharmacol. Ther.52,453–457 (1992).
  Medline CASGoogle Scholar
• 88  Modry D, Stinson E, Oyer P: Acute rejection and massive cyclosporine requirements in heart transplantation. Transplantation.39,313–314 (1985).
  Medline CASGoogle Scholar
• 89  Lin J, Lu A: Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet.35,361–390 (1998).
  Medline CASGoogle Scholar
• 90  Beresford A: CYP1A1: friend or foe? Drug Metab. Rev.25,503–517 (1993).
  Medline CASGoogle Scholar
• 91  Piacenti FJ: An update and review of antiretrovirals therapy. Pharmacotherapy26,1111–1133 (2006).
  Medline CASGoogle Scholar
• 92  Thummel KE, Wilkinson GR: In vitro and in vivo drug interactions involving human CYP3A. Ann. Rev. Pharmacol. Toxicol.38,389–430 (1998).
  Medline CASGoogle Scholar
• 93  Mahgoub A, Dring LG, Idle JR, Lancaster R, Smith RL: Polymorphic hydroxylation of debrisoquine in man. Lancet310,584–586 (1977).
  Google Scholar
• 94  Li AP, Rasmussen A, Xu L, Kaminski Dl: Rifampicin induction of lidocaine metabolism in cultured human hepatocytes. J. Pharmacol. Exp. Ther.274,673–677 (1995).
  Medline CASGoogle Scholar
• 95  Schuetz E, Schuetz J, Strom S et al.: Regulation of human liver cytochromes P-450 in family 3A in primary and continuous culture of human hepatocytes. Hepatology18,1254–1262 (1993).
  Medline CASGoogle Scholar
• 96  Gibbs JP, Hyland R, Youdim K: Minimizing polymorphic metabolism in drug discovery: evaluation of the utility of in vitro methods for predicting pharmacokinetic consequences associated with CYP2D6 metabolism. Drug Metab. Dispos.34,1516–1522 (2006).
  Medline CASGoogle Scholar
• 97  Saiki RK, Scharf S, Faloona F et al.: Enzymatic amplification of β-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science230,1350–1354 (1985).
  Medline CASGoogle Scholar
• 98  Rodríguez-Antona C, Jande M, Rane A, Ingelman-Sundberg M: Identification and phenotype characterization of two CYP3A haplotypes causing different enzymatic capacity in fetal livers. Clin. Pharmacol. Ther.77,259–270 (2005).
  Medline CASGoogle Scholar
• 99  Lee S-J, Jusko J, Salaita CG et al.: Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition. J. Clin. Pharmacol.46,515–526 (2006).
  Medline CASGoogle Scholar
• 100  Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR: CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B 5´-promoter region polymorphism. Clin. Pharmacol. Ther.68,82–91 (2000).
  Medline CASGoogle Scholar
• 101  Cheung C, Op Den Buijsch R, Wong K et al.: Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients. Pharmacogenomics7,563–574 (2006).
  CASGoogle Scholar
• 102  Lee S-J, Goldstein J: Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. Pharmacogenomics6,357–371 (2005).
  CASGoogle Scholar
• 103  Intemann CD, Thye T, Sievertsen J, Owusu-Dabo E, Horstmann RD, Meyer CG: Genotyping of IRGM tetranucleotide promoter oligorepeats by fluorescence resonance energy transfer. BioTechniques46,58–60 (2009).
  MedlineGoogle Scholar
• 104  Maurel P: The CYP3 family. In: Cytochromes P450: Metabolic and Toxicological Aspects. Edition. Ioannides C (Ed.). CRC, FL, USA, 241–270 (1996).
  Google Scholar
• 105  Quattrochi LC, Guzelian PS: CYP3A regulation: from pharmacology to nuclear receptors. Drug Metab. Dispos.29,615–622 (2001).
  Medline CASGoogle Scholar
• 106  Rae JM, Johnson MD, Lippman ME, Flockhart DA: Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J. Pharmacol. Exp. Ther.299,849–857 (2001).
  Medline CASGoogle Scholar
• 107  Bell AW, Michalopoulos GK: Phenobarbital regulates nuclear expression of HNF-4α in mouse and rat hepatocytes independent of CAR and PXR. Hepatology44,186–194 (2006).
  Medline CASGoogle Scholar
• 108  Usui T, Saitoh Y, Komada F: Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol. Pharm. Bull.26,510–517 (2003).
  Medline CASGoogle Scholar
• 109  Hukkanen J, Lassila A, Paivarinta K et al.: Induction and regulation of xenobiotic-metabolizing cytochrome P450s in the human A549 lung adenocarcinoma cell line. Am. J. Respir. Cell Mol. Biol.22,360–366 (2000).
  Medline CASGoogle Scholar
• 110  Zhou SF, Xue CC, Yu XQ, Li C, Wang G: Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther. Drug Monit.29,687–710 (2007).
  Medline CASGoogle Scholar
• 111  Cotreau M, von Moltke L, Greenblatt D: The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin. Pharmacokinet.44,33–60 (2005).
  Medline CASGoogle Scholar
• 112  Koudriakova T, Iatsimirskaia E, Utkin I et al.: Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: Mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab. Dispos.26,552–561 (1998).
  Medline CASGoogle Scholar
• 113  Chiba M, Hensleigh M, Lin JH: Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes: major role of CYP3A. Biochem. Pharmacol.53,1187–1195 (1997).
  Medline CASGoogle Scholar
• 114  Kumar GN, Rodrigues AD, Buko AM, Denissen JF: Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther.277,423–431 (1996).
  Medline CASGoogle Scholar
• 115  Zalma A, von Moltke LI, Granda BW, Harmatz JS, Shader RI, Greenblatt DJ: In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. Biological Psychiatry47,655–661 (2000).
  Medline CASGoogle Scholar
• 116  Greenblatt DJ, von Moltke Ll, Harmatz JS et al.: Differential impairment of triazolam and zolpidem clearance by ritonavir. J. Acquir. Immune Defic. Syndr.24,129–136 (2000).
  Medline CASGoogle Scholar
• 117  von Moltke Ll, Durol AL, Duan SX, Greenblatt DJ: Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole. Eur. J. Clin. Pharmacol.56,259–261 (2000).
  Medline CASGoogle Scholar
• 118  Eagling V, Back D, Barry M: Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br. J. Clin. Pharmacol.44,190–194 (1997).
  Medline CASGoogle Scholar
• 119  Chiba M, Hensleigh M, Nishime JA, Balani SK, Lin JH: Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos.24,307–314 (1996).
  Medline CASGoogle Scholar
• 120  Barry M, Gibbons S, Back D, Mulcahy F: Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin. Pharmacokinet.32,194–209 (1997).
  Medline CASGoogle Scholar
• 121  Kumar GN, Dykstra J, Roberts EM et al.: Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug–drug interaction. Drug Metab. Dispos.27,902–908 (1999).
  Medline CASGoogle Scholar
• 122  Goldsmith Dr, Perry CM: Atazanavir. Drugs63,1679–1693 (2003).
  Medline CASGoogle Scholar
• 123  Le Tiec C, Barrail A, Goujard C, Taburet A: Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin. Pharmacokinet.44,1035–1050 (2005).
  Medline CASGoogle Scholar
• 124  Lillibridge JH, Liang BH, Kerr BM et al.: Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab. Dispos.26,609–616 (1998).
  Medline CASGoogle Scholar
• 125  Zhang KE, Wu E, Patick AK et al.: Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. Antimicrob. Agents Chemother.45,1086–1093 (2001).
  Medline CASGoogle Scholar
• 126  Westlind A, Malmebo S, Johansson I et al.: Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43. Biochem. Biophys. Res. Commun.281,1349–1355 (2001).
  Medline CASGoogle Scholar
• 127  Kharasch Ed, Hoffer C, Whittington D, Sheffels P: Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin. Pharmacol. Ther.76,250–269 (2004).
  Medline CASGoogle Scholar
• 128  Goto M, Masuda S, Kiuchi T et al.: CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics14,471–478 (2004).
  Medline CASGoogle Scholar
• 129  Greenblatt DJ, von Moltke Ll, Harmatz JS et al.: Time course of recovery of cytochrome P450 3A function after single doses of grapefruit juice. Clin. Pharmacol. Ther.74,121–129 (2003).
  Medline CASGoogle Scholar
• 130  Rotger M, Colombo S, Furrer H et al.: Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet. Genomics.15,1–5 (2005).
  Medline CASGoogle Scholar
• 131  Wang J, Sonnerborg A, Rane A et al.: Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet. Genomics.16,191–198 (2006).
  MedlineGoogle Scholar
• 132  Stebbing J, Bower M: Comparative pharmacogenomics of antiretroviral and cytotoxic treatments. Lancet Oncol.7,61–68 (2006).
  Medline CASGoogle Scholar
• 133  Rodriguez-Novoa S, Barreiro P, Jimenez-Nacher I, Soriano V: Overview of the pharmacogenetics of HIV therapy. Pharmacogenomics J.6,234–245 (2006).
  Medline CASGoogle Scholar
• 134  Schwartz DH, Iyengar S: Toward genetic rationalization of antiretroviral therapy for HIV. AIDS19,975–977 (2005).
  MedlineGoogle Scholar
• 135  Haas DW: Will pharmacogenomic discoveries improve HIV therapeutics? Top. HIV Med.13,90–95 (2005).
  MedlineGoogle Scholar
• 136  Haas DW, Wilkinson GR, Kuritzkes DR et al.: A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128. HIV Clin. Trials4,287–300 (2003).
  MedlineGoogle Scholar
• 137  Haas DW: Pharmacogenomics and HIV therapeutics. J. Infect. Dis.191,1397–1400 (2005).
  Medline CASGoogle Scholar
• 138  Haas DW, Ribaudo HJ, Kim RB et al.: Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS18,2391–2400 (2004).
  Medline CASGoogle Scholar
• 139  Haas DW, Smeaton LM, Shafer RW et al.: Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J. Infect. Dis.192,1931–1942 (2005).
  Medline CASGoogle Scholar
• 140  Zhang X, Liu ZH, Zheng JM et al.: Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation. Clin. Transplant.19,638–643 (2005).
  MedlineGoogle Scholar
• 141  Kukanich B, Lascelles BD, Aman AM, Mealey KL, Papich MG: The effects of inhibiting cytochrome P450 3A, p-glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogs. J. Vet. Pharmacol. Ther.28,461–466 (2005).
  Medline CASGoogle Scholar
• 142  Christians U, Schmitz V, Haschke M: Functional interactions between P-glycoprotein and CYP3A in drug metabolism. Expert Opin. Drug Metab. Toxicol.1,641–654 (2005).
  Medline CASGoogle Scholar
• 143  Jones K, Hoggard P, Sales S, Khoo S, Davey R, Back D: Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. AIDS15,675–681 (2001).
  Medline CASGoogle Scholar
• 144  Anglicheau D, Thervet E, Etienne I et al.: CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin. Pharmacol. Ther.75,422–433 (2004).
  Medline CASGoogle Scholar
• 145  Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J. Pharmacol. Exp. Ther.303,323–332 (2002).
  Medline CASGoogle Scholar
• 146  Fellay J, Marzolini C, Meaden ER et al.: Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet359,30–36 (2002).
  Medline CASGoogle Scholar
• 147  Rodriguez Novoa S, Barreiro P, Rendon A et al.: Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C>T polymorphism at the multidrug resistance gene 1. Clin. Infect. Dis.42,291–295 (2006).
  MedlineGoogle Scholar
• 148  Bertilsson G, Berkenstam A, Blomquist P: Functionally conserved xenobiotic responsive enhancer in cytochrome P450 3A7. Biochem. Biophy. Res. Commun.280,139–144 (2001).
  Medline CASGoogle Scholar
• 149  Penzak S, Kabuye G, Mugyenyi P et al.: Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med.8,86–91 (2007).
  Medline CASGoogle Scholar
• 150  Haas DW, Bartlett JA, Andersen JW et al.: Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin. Infect. Dis.43783–786 (2006).
  Medline CASGoogle Scholar
• 151  Mouly SJ, Matheny C, Paine MF et al.: Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. Clin. Pharmacol. Ther.78,605–618 (2005).
  Medline CASGoogle Scholar
• 152  Josephson F, Allqvist A, Janabi M et al.: CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir. Clin. Pharmacol. Ther.81,708–712 (2007).
  Medline CASGoogle Scholar
• 153  Anderson P, Lamba J, Aquilante Cl, Schuetz E, Fletcher CV: Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J. Acquir. Immune Defic. Syndr.42,441–449 (2006).
  Medline CASGoogle Scholar
• 154  Rodriguez-Novoa S, Martin-Carbonero L, Barreiro P et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS21,41–46 (2007).
  Medline CASGoogle Scholar
• 155  Lamba J, Strom S, Venkataramanan R et al.: MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin. Pharmacol. Ther.79,325–338 (2006).
  Medline CASGoogle Scholar
• 156  Ma Q, Brazeau D, Forrest A, Morse GD: Advances in pharmacogenomics of antiretrovirals: an update. Pharmacogenomics8,1169–1178 (2007).
  CASGoogle Scholar
• 157  Hopkins MM, Ibarreta D, Gaisser S et al.: Putting pharmacogenetics into practice. Nat. Biotech.24,403–410 (2006).
  Medline CASGoogle Scholar
• 158  Staddon S, Arranz M, Mancama D, Mata I, Kerwin RW: Clinical applications of pharmacogenetics in psychiatry. Psychopharmacology (Berl.)162,18–23 (2002).
  Medline CASGoogle Scholar
• 159  Aquilante CL, Langaee TY, Lopez LM et al.: Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin. Pharmacol. Ther.79,291–302 (2006).
  Medline CASGoogle Scholar
• 160  Martin AM, Nolan D, Gaudieri S et al.: Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. PNAS101,4180–4185 (2004).
  Medline CASGoogle Scholar
• 161  Abraham J, Earl H, Pharoah P, Caldas C: Pharmacogenetics of cancer chemotherapy. Biochim. Biophys. Acta1766,168–183 (2006).
  Medline CASGoogle Scholar
• 162  Weinshilboum R, Wang L: Pharmacogenomics: bench to bedside. Nat. Rev. Drug Discov.3,739–748 (2004).
  Medline CASGoogle Scholar
• 163  Roden DM, Altman RB, Benowitz NL et al.: Pharmacogenomics: challenges and opportunities. Ann. Intern. Med.145,749–757 (2006).
  MedlineGoogle Scholar
• 164  Murray M: Induction and inhibition of CYPs and implications for medicine. Mol. Aspects Med.20,34–137 (1999).
  Google Scholar
• 165  Winzer R, Langmann P, Zilly M et al.: No influence of the P-glycoprotein polymorphisms MDR1 G2677T/A and C3435T on the virological and immunological response in treatment naive HIV-positive patients. Ann. Clin. Microbiol. Antimicrob.4,3 (2005).
  MedlineGoogle Scholar
• 166  Wilkinson GR: Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity: some answers but still questions. Clin. Pharmacol. Ther.76,99–103 (2004).
  Medline CASGoogle Scholar
• 167  Quirk E, Mcleod H, Powderly W: The pharmacogenetics of antiretroviral therapy: a review of studies to date. Clin. Infect. Dis.39,98–106 (2004).
  Medline CASGoogle Scholar
• 168  Martin A, Nolan D, Gaudieri S, Phillips E, Mallal S: Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity. Pharmacogenomics5,643–655 (2004).
  CASGoogle Scholar
• 169  Saitoh A, Singh K, Powell C et al.: An MDR1 -3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS19,371–380 (2005).
  Medline CASGoogle Scholar
• 170  Nolan D, Gaudieri S, Mallal S: Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity? J. HIV Ther.8,36–41 (2003).
  Medline CASGoogle Scholar
• 171  Haas DW, Wu H, Li H et al.: MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study. J. Acquir. Immune Defic. Syndr.34,295–298 (2003).
  Medline CASGoogle Scholar
• 172  Motsinger A, Ritchie M, Shafer RW et al.: Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study. Pharmacogenet. Genomics.16,837–845 (2006).
  Medline CASGoogle Scholar
• 173  Rae JM, Johnson MD, Lippman ME, Flockhart DA: Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes:studies with cDNA and oligonucleotide arrays. J. Pharmacol. Exp. Ther.299,849–857 (2001).
  Medline CASGoogle Scholar
• 174  Usui T, Saitoh Y, Komada F: Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol. Pharm. Bull.26,510–517 (2003).
  Medline CASGoogle Scholar
• 175  Luo G, Cunningham M, Kim S et al.: CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab. Dispos.30,795–804 (2002).
  Medline CASGoogle Scholar
• 176  Hukkanen J, Lassila A, Paivarinta K et al.: Induction and regulation of xenobiotic-metabolizing cytochrome P450s in the human A549 lung adenocarcinoma cell line. Am. J. Respir. Cell Mol. Biol.22,360–366 (2000).
  Medline CASGoogle Scholar
• 177  Krusekopf S, Roots I, Kleeberg U: Differential drug-induced mRNA expression of human CYP3A4 compared with CYP3A5, CYP3A7 and CYP3A43. Eur. J. Pharmacol.466,7–12 (2003).
  Medline CASGoogle Scholar
• 178  Raucy JL: Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab. Dispos.31,533–539 (2003).
  Medline CASGoogle Scholar